REMS Assessments Need Very Recent Data, FDA Draft Guidance Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors conducting assessments of a product’s Risk Evaluation and Mitigation Strategy will need to complete them within 60 days of collecting the last piece of data, according to a draft FDA guidance.